Squamous cell carcinoma antigen recognized by T cells 3 (SART3) (SART3)

Squamous cell carcinoma antigen recognized by T cells 3 (SART3), also known as p110 or TIP110, is a nuclear RNA-binding protein that plays a pivotal role in the pre-mRNA splicing machinery. It functions as a recycling factor for the U4/U6 snRNP, ensuring the efficient reassembly of the spliceosome required for gene expression (UniProt: Q15020). SART3 also acts as a scaffold for deubiquitinating enzymes such as USP7, thereby regulating the stability of proteins involved in various cellular pathways (PubMed: 20133608). In clinical oncology, SART3 is recognized as a tumor-associated antigen (TAA) that is overexpressed in various cancers, including squamous cell carcinoma, colorectal cancer, and leukemia, while showing minimal expression in normal tissues (PubMed: 10359051). This differential expression makes it an attractive target for immunotherapy, particularly peptide-based vaccines aimed at eliciting a cytotoxic T lymphocyte (CTL) response (PubMed: 21415215). Furthermore, SART3 has been identified as a co-factor in HIV-1 infection, where it interacts with the viral Tat protein to promote viral transcription (PubMed: 12105240). Therapeutic strategies targeting SART3 primarily focus on its immunogenic properties to treat advanced malignancies.

Other names

SART-3p110Tat-interacting protein of 110 kDaTIP110Spliceosome-associated protein 110RP11-439E19.3

Induction of antigen-specific cytotoxic T lymphocyte (CTL) response through HLA-restricted peptide presentation.